To: EasyWay who wrote (197 ) 2/17/1999 10:14:00 AM From: Micro-Selector Read Replies (1) | Respond to of 285
Here is a response I received from the company last 11/98. In the meantime, SYBD is a company with three promising biotech products, patent for last of them nearing completion, and clinical trials for all three scheduled to begin in 1999. IMO, SYBD is definitely worth a look while AMDD only worth a wait while it tries to secure much-needed funding. (And YES, this is an obvious push for SYBD which I own and believe in. Frankly, I am very disappointed with AMDD and will only support them in the future if they show signs of getting their company in order.) Regards, MicroSubject: ATTN: Paul Knopick Date: Sun, 22 Nov 1998 11:20:07 -0500 From: XXXX To: mkt@amdl.com Mr. Knopick: As a longtime shareholder of AMDL (pre-split), I am concerned about the future of AMDL. As stated in the latest news releases, the company has the necessary finances to fund itself through the end of this year. Is the company aggressively pursuing marketing or distributors for its products, specifically the Cancer Screening Kit? Are promising funding agreements in process or on the way? Any information you can provide (or if you could refer this message to someone who may have a more realistic idea if you do not) would be greatly appreciated as to whether AMDL sees itself continuing as a viable corporation moving toward profitability and successful marketing of its products, or is considering or planning dissolution. Thanks for your help, XXXXXXXX ---------------------- Dear XXXX: The company has been aggressively searching for recapitalization and continues to be reasonably optimistic that it can accomplish this. No distributor is going to sign up for a new product if it believes the company providing the product might not be around within a few months. The influx of capital has to come first and that's where AMDL has put its efforts. Paul Knopick